We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Press & Announcements

Latest Wound Care Research from Organogenesis Highlighted at SAWC Spring 2019

Canton, MA and and San Antonio, TX , April 30, 2019 – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced today that the latest research on NuShield® and PuraPly® Antimicrobial will be presented at the Symposium on Advanced Wound Care Spring | Wound Healing Society (SAWC Spring | WHS) 2019 meeting, held May 7-11 in San Antonio.

Research highlights include two NuShield® podium presentations on the WHS track.

"Dehydrated Amnion Chorion Membranes Induce Broad-scale Changes in Kinase Activity of Endothelial Cells" will be presented by Miranda Burnette, Ph.D., John P. McQuilling, Ph.D., MaryRose Kammer, Kelly A. Kimmerling, and Katie C. Mowry on Wednesday, May 8 from 4:55 to 5:05 p.m. in Meeting Room 006 B-D.

"In Vivo Evaluation of Angiogenic Properties of a Dehydrated Amnion Chorion Membrane" will be presented by John P. McQuilling, Ph.D., MaryRose Kammer, Kelly Kimmerling, and Katie C. Mowry on Friday, May 10 from 10:40 to 10:50 a.m. in Meeting Room 007 D.

Educational opportunities at the Organogenesis booth (#407) will include a wet lab demonstration of the Organogenesis wound care product portfolio.

Organogenesis will also sponsor a lunch symposium called "Breaking Biofilms and Advancing Healing" on Wednesday, May 8 from 12 to 1:30 p.m.

"Each year, the Symposium on Advanced Wound Care and the Wound Healing Society provide invaluable forums for the clinical and research communities to discuss the latest developments in wound healing," said Shabnam Vaezzadeh, MD, MPA, Vice President of Global Medical and Clinical Affairs for Organogenesis. "We look forward to sharing new medical and scientific evidence for our products with the wound care community."

RESEARCH PRESENTATIONS OF INTEREST INCLUDE:

PODIUM PRESENTATIONS

Dehydrated Amnion Chorion Membranes Induce Broad-scale Changes in Kinase Activity of Endothelial Cells
Miranda Burnette, John P. McQuilling, MaryRose Kammer, Kelly A. Kimmerling, Katie C. Mowry
Date: Wednesday, May 8 Time: 4:55 - 5:05 p.m. Location: 006 B-D

In Vivo Evaluation of Angiogenic Properties of a Dehydrated Amnion Chorion Membrane
John P. McQuilling, MaryRose Kammer, Kelly Kimmerling, Katie C. Mowry
Date: Friday, May 10 Time: 10:40 - 10:50 a.m. Location: 007 D

POSTER PRESENTATIONS

In-vitro study evaluating the sustained released effects of antimicrobial products against Methicillin-resistant Staphylococcus aureus (MRSA)
Alexander Higa, Joel Gil, Jose Valdes, Michael Solis, Stephen C. Davis

Combined Sequential effect of purified native type I collagen plus polyhexamethylene biguanide, followed by placental allograft on chronic wounds of various etiologies: a case series
George Koullias

Use of dehydrated amnion/chorion membrane (dACM) to treat non-healing leg ulcers caused by pyoderma gangrenosum
Windy Cole

Use of dehydrated amnion/chorion membrane (dACM) in a slow healing trauma wound
Susan Rolniak St. John, Dawn Wang, Jodi Boory, Janie Hollenbach

Broad Proteomic Analysis of a Dehydrated Amnion Chorion Membrane
Miranda Burnette, John P. McQuilling, MaryRose Kammer, Kelly A. Kimmerling, Katie C. Mowry

Dehydrated Amnion Chorion Membranes Induce Broad-scale Changes in Kinase Activity of Endothelial Cells
Miranda Burnette, John P. McQuilling, MaryRose Kammer, Kelly A. Kimmerling, Katie C. Mowry

In Vivo Evaluation of Angiogenic Properties of a Dehydrated Amnion Chorion Membrane
John P. McQuilling, MaryRose Kammer, Kelly Kimmerling, Katie C. Mowry

About Organogenesis Holdings Inc.

Organogenesis is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. To learn more, please see www.organogenesis.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to new evidence regarding the efficacy of our products. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward looking statements. These risks and uncertainties include the fact that rapid technological change could cause our products to become obsolete and if we do not enhance our product offerings through our research and development efforts, we may be unable to effectively compete, and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of our Form 10-K for the year ended December 31, 2018. Although we may voluntarily do so from time to time, we undertake no commitment to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Press and Media Inquiries:

Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500

Press and Media Inquiries:

Organogenesis
Angelyn Lowe
alowe@organo.com
781-774-9364


« Back to Press Releases and Announcements